These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 24998601

  • 1. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
    Rolfo C, Passiglia F, Russo A, Pauwels P.
    Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
    [Abstract] [Full Text] [Related]

  • 2. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C.
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [Abstract] [Full Text] [Related]

  • 3. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB, De Langen AJ, Honeywell RJ, Giovannetti E, Peters GJ.
    Expert Rev Anticancer Ther; 2016 Mar; 16(2):147-57. PubMed ID: 26654422
    [Abstract] [Full Text] [Related]

  • 4. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 8. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Sep 01; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 9. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.
    Expert Opin Investig Drugs; 2017 Jun 01; 26(6):713-722. PubMed ID: 28463570
    [Abstract] [Full Text] [Related]

  • 10. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF.
    Future Oncol; 2014 Oct 01; 10(12):1925-39. PubMed ID: 24856155
    [Abstract] [Full Text] [Related]

  • 11. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.
    Cancer Treat Rev; 2017 Apr 01; 55():181-189. PubMed ID: 28427013
    [Abstract] [Full Text] [Related]

  • 12. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Straughan DM, Azoury SC, Shukla V.
    Curr Drug Targets; 2016 Apr 01; 17(6):739-45. PubMed ID: 26073862
    [Abstract] [Full Text] [Related]

  • 13. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
    Landi L, Cappuzzo F.
    Expert Rev Clin Pharmacol; 2016 Apr 01; 9(2):203-14. PubMed ID: 26582431
    [Abstract] [Full Text] [Related]

  • 14. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.
    J Thorac Oncol; 2016 Sep 01; 11(9):1550-7. PubMed ID: 27288979
    [Abstract] [Full Text] [Related]

  • 15. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
    Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.
    Drug Des Devel Ther; 2017 Sep 01; 11():2047-2063. PubMed ID: 28740365
    [Abstract] [Full Text] [Related]

  • 16. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.
    Cancer Discov; 2014 Jun 01; 4(6):662-673. PubMed ID: 24675041
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 01; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 18. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.
    J Clin Oncol; 2016 Aug 20; 34(24):2866-73. PubMed ID: 27432917
    [Abstract] [Full Text] [Related]

  • 19. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 20; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 20. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R, Greystoke A, Lal R, Thompson J, Popat S.
    Lung Cancer; 2017 Sep 20; 111():51-58. PubMed ID: 28838397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.